After Hours Summary: HEI up on earnings, BA lower on MAX suspensionAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: HEI +2.3% (also increases dividend)
Companies trading higher in after hours in reaction to news: AGIO +4.8% (receives Breakthrough Therapy Designation for TIBSOVA from the FDA), ONCE +0.8% (FTC closes Roche investigation), LLY +0.5% {dividend increase), OFLX +0.4% declares special dividend of $3.50 per share), KALU +0.3% (announces new five year labor agreement)
After Hours Losers:
Companies trading lower in after hours in reaction to news: MEIP -23.1% (announces offering), CLVS -10.7% (files for $250 mln mixed shelf offering), CARS -3% (CEO resigns), ROKU -2.9% (CFO to step down), APTO -0.9% (announces offering), BA -0.6% (confirms it will suspend 737 MAX production in Jan)
![]()
Closing Stock Market SummaryThe stock market rose further into record territory on Monday, as the Phase One trade deal and an improving Chinese economy helped maintain the market's bullish bias. The Nasdaq Composite (+0.9%) rose above the S&P 500 (+0.7%), Dow Jones Industrial Average (+0.4%), and Russell 2000 (+0.7%).
The initial reaction to the trade deal was muted on Friday, so today was less about the actual deal and more about what it means moving forward: less uncertainty, and optimism, in the economic outlook. This view contributed to Monday's strong open, which accounted for most of today's gains as the S&P 500 drifted sideways for most of the session.
China's industrial production and retail sales figures, which grew faster than expected in November, added to the positive economic outlook also shared by the homebuilders. For instance, the NAHB Housing Market Index hit its highest level since 1999, increasing to 76 in December (Briefing.com consensus 69) from 69 in November.
The S&P 500 energy (+1.4%), utilities (+1.3%), and health care (+1.1%) sectors each rose more than 1.0%. The market also continued to draw influential support from Apple (AAPL 279, +4.71, +1.7%).
Conversely, the industrials sector (-0.03%) was pressured by weakness in shares of Boeing (BA 327.00, -14.67, -4.3%) and FedEx (FDX 164.10, -1.57, -1.0%) following separate reports from The Wall Street Journal.
Boeing is reportedly considering halting or cutting back production for its 737 MAX amid continued re-certification uncertainty. Amazon (AMZN 1769.21, +8.27, +0.5%) reportedly banned third-party sellers from using FedEx Ground for Prime shipments until delivery performance improves.
In M&A activity, DuPont (DD 64.89, +0.09, +0.1%) agreed to merge its Nutrition & Biosciences unit with International Flavors (IFF 120.00, -13.98, -10.4%) in a combined $45.4 billion deal. WPX Energy (WPX 11.90, +0.99, +9.1%) agreed to purchase Felix Energy for $2.5 billion.
U.S. Treasuries finished on a lower note, driving yields higher in a curve-steepening trade. The 2-yr yield increased three basis points to 1.53%, and the 10-yr yield increased seven basis points to 1.89%. The U.S. Dollar Index declined 0.1% to 97.05. WTI crude increased 0.2%, or $0.10, to $60.21/bbl.
Reviewing Monday's economic data:
- The NAHB Housing Market Index for December increased to 76 (consensus 69) from 69 in November, hitting its highest level since 1999.
- The Empire State Manufacturing Survey for December increased to 3.5 (consensus 3.5) from the prior month's reading of 2.9.
Looking ahead, investors will receive Housing Starts and Building Permits for November, Industrial Production and Capacity Utilization for November, and the JOLTS - Job Openings survey for October on Tuesday.
- Nasdaq Composite +32.8% YTD
- S&P 500 +27.3% YTD
- Russell 2000 +22.4% YTD
- Dow Jones Industrial Average +21.0% YTD
In reaction to disappointing earnings/guidance:
- N/A.
M&A news:
- IFF -5.4% (Intl Flavors to merge with DuPont's (DD) Nutrition & Biosciences business; deal values the combined company at $45.4 bln; both IFF and DD reaffirm FY19 guidance)
Other news:
- GOSS -31% (trading lower once again following negative updated from Novertis (NVS) DP2 antagonist Fevipiprant)
- PCG -26% (California Governor Gavin Newsom rejects PG&E reorganization plan)
- BGNE -9.8% (announces results of phase 3 aspen trial of zanubrutinib compared to ibrutinib for the treatment of patients with waldenström's macroglobulinemia; primary endpoint of statistical superiority related to deep response (vgpr or better) was not met)
- WPX -3.9% (to purchase Felix Energy for $2.5 bln; Transaction is accretive on all important metrics: EPS, CFPS, FCF per share, ROCE and NAV)
- NK -3.1% (NantKwest and ImmunityBio present results of landmark trial of first-in-human natural killer cell combination immunotherapy with durable, complete response data and 78% disease control in refractory triple negative breast cancer at SABCS)
- FRTA -1.4% (files for ~45.1 mln share common stock offering by selling stockholders)
- QTNT -1.1% (entered into a Registration Rights Agreement with its CEO, Chairman, and CFO with respect to an aggregate of 105,000 ordinary shares owned by these individuals)
Analyst comments:
- URBN -1.7% (downgraded to Hold from Buy at Loop Capital)
- CRS -1.4% (downgraded to Neutral from Buy at Longbow)
- REGN -1.4% (downgraded to In-line from Outperform at Evercore ISI)
- PEP -0.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
In reaction to strong earnings/guidance:
- N/A.
M&A news:
- DD +3.4% (Intl Flavors to merge with DuPont's (DD) Nutrition & Biosciences business; deal values the combined company at $45.4 bln; both IFF and DD reaffirm FY19 guidance)
Select financial related names showing strength:
- BCS +3.3%, LYG +2%, HSBC +2%, DB +1.9%, BBVA +1.5%, SAN +1.5%, RBS +1.2%, GS +1.1%
Other news:
- AXSM +82.2% (announces axs-05 achieves primary endpoint in gemini phase 3 trial in major depressive disorder; AXS-05 met the primary endpoint)
- AMRN +7.3% (FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups)
- HZNP +6.6% (Horizon Pharma confirms unanimous FDA DODAC vote to support the use of teprotumumab for the treatment of Thyroid Eye Disease )
- GLOG +5.6% (announces newbuild financing facility, enhancements to existing facilities and payment of special dividend of $0.38/share)
- KURA +3.2% (receives fast track designation for Tipifarnib in HRAS mutant hnscc and provides enrollment guidance for AIM-HN Trial)
- ATNX +2.4% (expands its strategic partnership with Guangzhou Xiangxue Pharmaceutical through a licensing agreement for its product candidates oral paclitaxel and oral irinotecan, as well as tirbanibulin ointment, in China, Hong Kong and Macao)
- ETRN +2% (Equitrans Midstream and EQM Midstream Partners (EQM) provide 2020 financial and CAPEX guidance)
- ESRT +1.7% (reauthorizes the repurchase of up to $500 million of Class A common stock, and ESRO's Series ES, Series 250 and Series 60 operating partnership units)
- SCVL +1% (authorizes new share repurchase program for up to $50 mln of outstanding common stock, effective January 1, 2020)
Analyst comments:
- ELF +7.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- WDC +3.4% (upgraded to Positive from Neutral at Susquehanna)
- MU +3.2% (upgraded to Positive from Neutral at Susquehanna)
- KMT +2% (upgraded to Overweight from Equal Weight at Wells Fargo)
- COHR +1.7% (upgraded to Positive from Neutral at Susquehanna)
- AGCO +1.5% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- SPB +1.3% (upgraded to Outperform from Perform at Oppenheimer)
- GS +1.1% (upgraded to Buy from Neutral at Citigroup)
- USB +0.8% (upgraded to Neutral from Sell at Citigroup)